Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations

Koji Takami, Hiroki Inui, Koichi Nagayama, Masahiro Watatani, Masayuki Yasutomi, Hiroki Kurahashi, Takesada Mori, Shin Ichiro Takai, Isamu Nishisho

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

MDM2 protein is thought to bind to p53 tumor suppressor protein leading to inhibition of p53-mediated transactivation. Amplification of the MDM2 gene has been frequently observed in human sarcoma, and relevant overexpression of the MDM2 protein is assumed to contribute to tumor-igenesis through inactivation of the p53 function. In order to determine whether MDM2 amplification plays a role in the development of human breast cancer without genetic alteration of p53, we analyzed, MDM2 gene amplification by quantitative hybridization and genetic alteration of p53, in 32 primary tumors and 26 metastatic lymph nodes. Low grade amplification of the MDM2 gene (2-6 fold) was observed in four cases, none of which showed even subtle genetic alterations of p53 or loss of alleles on 17p. Moreover, in three of the four cases with MDM2 gene amplification, the level of gene amplification in the metastatic lymph nodes was slightly higher than that in the primary tumors. These results, taken together with previous findings, suggest that a subset of breast cancers without genetic alteration of p53 may also arise by inactivation of the p53 function through interaction with the overexpressed MDM2 protein induced by gene amplification.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalBreast Cancer
Volume1
Issue number2
DOIs
Publication statusPublished - 01-01-1994

Fingerprint

Gene Amplification
Breast Neoplasms
Lymph Nodes
Genetic Hybridization
Tumor Suppressor Protein p53
Neoplasms
Proteins
Human Development
Sarcoma
Transcriptional Activation
Alleles

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Takami, K., Inui, H., Nagayama, K., Watatani, M., Yasutomi, M., Kurahashi, H., ... Nishisho, I. (1994). Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations. Breast Cancer, 1(2), 95-102. https://doi.org/10.1007/BF02967038
Takami, Koji ; Inui, Hiroki ; Nagayama, Koichi ; Watatani, Masahiro ; Yasutomi, Masayuki ; Kurahashi, Hiroki ; Mori, Takesada ; Takai, Shin Ichiro ; Nishisho, Isamu. / Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations. In: Breast Cancer. 1994 ; Vol. 1, No. 2. pp. 95-102.
@article{3f36c041a6ca434a8c3dae98817dba7c,
title = "Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations",
abstract = "MDM2 protein is thought to bind to p53 tumor suppressor protein leading to inhibition of p53-mediated transactivation. Amplification of the MDM2 gene has been frequently observed in human sarcoma, and relevant overexpression of the MDM2 protein is assumed to contribute to tumor-igenesis through inactivation of the p53 function. In order to determine whether MDM2 amplification plays a role in the development of human breast cancer without genetic alteration of p53, we analyzed, MDM2 gene amplification by quantitative hybridization and genetic alteration of p53, in 32 primary tumors and 26 metastatic lymph nodes. Low grade amplification of the MDM2 gene (2-6 fold) was observed in four cases, none of which showed even subtle genetic alterations of p53 or loss of alleles on 17p. Moreover, in three of the four cases with MDM2 gene amplification, the level of gene amplification in the metastatic lymph nodes was slightly higher than that in the primary tumors. These results, taken together with previous findings, suggest that a subset of breast cancers without genetic alteration of p53 may also arise by inactivation of the p53 function through interaction with the overexpressed MDM2 protein induced by gene amplification.",
author = "Koji Takami and Hiroki Inui and Koichi Nagayama and Masahiro Watatani and Masayuki Yasutomi and Hiroki Kurahashi and Takesada Mori and Takai, {Shin Ichiro} and Isamu Nishisho",
year = "1994",
month = "1",
day = "1",
doi = "10.1007/BF02967038",
language = "English",
volume = "1",
pages = "95--102",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

Takami, K, Inui, H, Nagayama, K, Watatani, M, Yasutomi, M, Kurahashi, H, Mori, T, Takai, SI & Nishisho, I 1994, 'Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations', Breast Cancer, vol. 1, no. 2, pp. 95-102. https://doi.org/10.1007/BF02967038

Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations. / Takami, Koji; Inui, Hiroki; Nagayama, Koichi; Watatani, Masahiro; Yasutomi, Masayuki; Kurahashi, Hiroki; Mori, Takesada; Takai, Shin Ichiro; Nishisho, Isamu.

In: Breast Cancer, Vol. 1, No. 2, 01.01.1994, p. 95-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations

AU - Takami, Koji

AU - Inui, Hiroki

AU - Nagayama, Koichi

AU - Watatani, Masahiro

AU - Yasutomi, Masayuki

AU - Kurahashi, Hiroki

AU - Mori, Takesada

AU - Takai, Shin Ichiro

AU - Nishisho, Isamu

PY - 1994/1/1

Y1 - 1994/1/1

N2 - MDM2 protein is thought to bind to p53 tumor suppressor protein leading to inhibition of p53-mediated transactivation. Amplification of the MDM2 gene has been frequently observed in human sarcoma, and relevant overexpression of the MDM2 protein is assumed to contribute to tumor-igenesis through inactivation of the p53 function. In order to determine whether MDM2 amplification plays a role in the development of human breast cancer without genetic alteration of p53, we analyzed, MDM2 gene amplification by quantitative hybridization and genetic alteration of p53, in 32 primary tumors and 26 metastatic lymph nodes. Low grade amplification of the MDM2 gene (2-6 fold) was observed in four cases, none of which showed even subtle genetic alterations of p53 or loss of alleles on 17p. Moreover, in three of the four cases with MDM2 gene amplification, the level of gene amplification in the metastatic lymph nodes was slightly higher than that in the primary tumors. These results, taken together with previous findings, suggest that a subset of breast cancers without genetic alteration of p53 may also arise by inactivation of the p53 function through interaction with the overexpressed MDM2 protein induced by gene amplification.

AB - MDM2 protein is thought to bind to p53 tumor suppressor protein leading to inhibition of p53-mediated transactivation. Amplification of the MDM2 gene has been frequently observed in human sarcoma, and relevant overexpression of the MDM2 protein is assumed to contribute to tumor-igenesis through inactivation of the p53 function. In order to determine whether MDM2 amplification plays a role in the development of human breast cancer without genetic alteration of p53, we analyzed, MDM2 gene amplification by quantitative hybridization and genetic alteration of p53, in 32 primary tumors and 26 metastatic lymph nodes. Low grade amplification of the MDM2 gene (2-6 fold) was observed in four cases, none of which showed even subtle genetic alterations of p53 or loss of alleles on 17p. Moreover, in three of the four cases with MDM2 gene amplification, the level of gene amplification in the metastatic lymph nodes was slightly higher than that in the primary tumors. These results, taken together with previous findings, suggest that a subset of breast cancers without genetic alteration of p53 may also arise by inactivation of the p53 function through interaction with the overexpressed MDM2 protein induced by gene amplification.

UR - http://www.scopus.com/inward/record.url?scp=0002268606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002268606&partnerID=8YFLogxK

U2 - 10.1007/BF02967038

DO - 10.1007/BF02967038

M3 - Article

AN - SCOPUS:0002268606

VL - 1

SP - 95

EP - 102

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -